Goldman Sachs
NAVB

Goldman Sachs’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Goldman Sachs’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-6,701
Closed -$31K – 5902
2018
Q3 		$31K Buy
6,701
+5
+0.1% +$19 ﹤0.01% 5370
2018
Q2 		$31K Buy
6,696
+9
+0.1% +$47 ﹤0.01% 5448
2018
Q1 		$48K Buy
6,687
+11
+0.2% +$82 ﹤0.01% 5482
2017
Q4 		$48K Sell
6,676
-6,427
-49% -$54.4K ﹤0.01% 5945
2017
Q3 		$109K Sell
13,103
-1,827
-12% -$15.5K ﹤0.01% 6026
2017
Q2 		$152K Sell
14,930
-2,386
-14% -$23.6K ﹤0.01% 5942
2017
Q1 		$200K Sell
17,316
-23,520
-58% -$267K ﹤0.01% 5733
2016
Q4 		$521K Sell
40,836
-10,290
-20% -$163K ﹤0.01% 5031
2016
Q3 		$936K Sell
51,126
-163,071
-76% -$2.06M ﹤0.01% 4467
2016
Q2 		$2.27M Buy
214,197
+33,700
+19% +$662K ﹤0.01% 3511
2016
Q1 		$3.41M Sell
180,497
-14,400
-7% -$277K ﹤0.01% 3028
2015
Q4 		$5.18M Sell
194,897
-3,164
-2% -$110K ﹤0.01% 2790
2015
Q3 		$9.03M Sell
198,061
-12,033
-6% -$454K ﹤0.01% 2332
2015
Q2 		$6.76M Buy
210,094
+49,255
+31% +$1.43M ﹤0.01% 2671
2015
Q1 		$5.12M Buy
160,839
+156,159
+3,337% +$5.28M ﹤0.01% 2871
2014
Q4 		$177K Buy
4,680
+3,678
+367% +$101K ﹤0.01% 6259
2014
Q3 		$26K Sell
1,002
-1,051
-51% -$27.8K ﹤0.01% 6956
2014
Q2 		$61K Sell
2,053
-1,831
-47% -$59.2K ﹤0.01% 6709
2014
Q1 		$144K Buy
3,884
+575
+17% +$21.8K ﹤0.01% 6255
2013
Q4 		$137K Buy
3,309
+975
+42% +$38.2K ﹤0.01% 6151
2013
Q3 		$124K Sell
2,334
-2,080
-47% -$121K ﹤0.01% 6092
2013
Q2 		$236K Buy
+4,414
New +$220K ﹤0.01% 5480

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs's NAVB Position: Q4 2018 in Review

Goldman Sachs sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q4 2018, closing a stake of 6,701 shares — an estimated $31K sold.

Goldman Sachs first reported a position in NAVB in Q2 2013 and held it in 22 quarters. The position peaked at $9.03M in Q3 2015. 56 funds tracked by Wall St. Rank hold NAVB as of Q4 2018.

  • Goldman Sachs reported no remaining Navidea Biopharmaceuticals Inc. position as of Q4 2018 after selling out during the quarter.
  • Goldman Sachs sold 6,701 Navidea Biopharmaceuticals Inc. shares in Q4 2018, an estimated $31K.
  • Goldman Sachs first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and held it in 22 quarters.
  • Goldman Sachs's Navidea Biopharmaceuticals Inc. position peaked at $9.03M in Q3 2015.
  • 56 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2018.

Based on Goldman Sachs's 13F filing for Q4 2018, filed 14 Feb 2019.